I-Mab (IMAB) Stock Forecast, Price Target & Predictions
IMAB Stock Forecast
I-Mab stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
IMAB Analyst Ratings
According to 2 Wall Street analysts, I-Mab's rating consensus is 'Buy'. The analyst rating breakdown for IMAB stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 18, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 17, 2022 | Needham | Buy | Buy | Hold |
| Jun 07, 2022 | Piper Sandler | Overweight | Overweight | Hold |
I-Mab's last stock rating was published by Piper Sandler on Sep 16, 2024. The company gave IMAB a "Overweight" rating, the same as its previous rate.
I-Mab Financial Forecast
I-Mab Revenue Forecast
| Mar 27 | Sep 26 | Jun 26 | Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | $10.71M | $10.71M | - | $549.94M | $239.97M | $957.27M | - | $5.45M | $934.72K | $14.17M |
| High Forecast | - | $10.71M | $10.71M | - | $549.94M | $239.97M | $957.27M | - | $5.45M | $934.72K | $14.17M |
| Low Forecast | - | $10.71M | $10.71M | - | $549.94M | $239.97M | $957.27M | - | $5.45M | $934.72K | $14.17M |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
I-Mab's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMAB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
I-Mab EBITDA Forecast
| Mar 27 | Sep 26 | Jun 26 | Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | $-3.61M | $-3.61M | - | $-185.46M | $-80.93M | $-322.83M | - | $-1.84M | $-315.22K | $-4.78M |
| High Forecast | - | $-3.61M | $-3.61M | - | $-185.46M | $-80.93M | $-322.83M | - | $-1.84M | $-315.22K | $-4.78M |
| Low Forecast | - | $-3.61M | $-3.61M | - | $-185.46M | $-80.93M | $-322.83M | - | $-1.84M | $-315.22K | $-4.78M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict IMAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than I-Mab's previous annual EBITDA (undefined) of $NaN.
I-Mab Net Income Forecast
| Mar 27 | Sep 26 | Jun 26 | Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-86.70M | - | $-190.10M | $-398.75M | $144.50M | $-384.32M | $714.02M | $-329.47M | $-282.29M | $877.90M | $-481.60M |
| High Forecast | $-86.70M | - | $-190.10M | $-398.75M | $144.50M | $-384.32M | $714.02M | $-329.47M | $-282.29M | $877.90M | $-481.60M |
| Low Forecast | $-86.70M | - | $-190.10M | $-398.75M | $144.50M | $-384.32M | $714.02M | $-329.47M | $-282.29M | $877.90M | $-481.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
I-Mab's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
I-Mab SG&A Forecast
| Mar 27 | Sep 26 | Jun 26 | Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | $97.36M | $97.36M | - | $5.00B | $2.18B | $8.70B | - | $49.53M | $8.49M | $128.76M |
| High Forecast | - | $97.36M | $97.36M | - | $5.00B | $2.18B | $8.70B | - | $49.53M | $8.49M | $128.76M |
| Low Forecast | - | $97.36M | $97.36M | - | $5.00B | $2.18B | $8.70B | - | $49.53M | $8.49M | $128.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
I-Mab's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMAB last annual SG&A of $NaN (undefined).
I-Mab EPS Forecast
| Mar 27 | Sep 26 | Jun 26 | Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-1.07 | - | $-2.35 | $-4.93 | $1.79 | $-4.75 | $8.82 | $-4.07 | $-3.49 | $11.40 | $-5.95 |
| High Forecast | $-1.07 | - | $-2.35 | $-4.93 | $1.79 | $-4.75 | $8.82 | $-4.07 | $-3.49 | $11.40 | $-5.95 |
| Low Forecast | $-1.07 | - | $-2.35 | $-4.93 | $1.79 | $-4.75 | $8.82 | $-4.07 | $-3.49 | $11.40 | $-5.95 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, I-Mab's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMAB previous annual EPS of $NaN (undefined).
I-Mab Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IMAB | I-Mab | $1.09 | $35.00 | 3111.01% | Buy |
| LYEL | Lyell Immunopharma | $1.39 | $9.50 | 583.45% | Hold |
| STTK | Shattuck Labs | $3.75 | $12.00 | 220.00% | Buy |
| ERAS | Erasca | $2.89 | $7.00 | 142.21% | Buy |
| APLS | Apellis Pharmaceuticals | $35.53 | $75.38 | 112.16% | Buy |
| CGEM | Cullinan Oncology | $17.24 | $32.00 | 85.61% | Buy |
| FHTX | Foghorn Therapeutics | $9.84 | $18.00 | 82.93% | Buy |
| AKRO | Akero Therapeutics | $26.64 | $46.00 | 72.67% | Buy |
| DSGN | Design Therapeutics | $5.77 | $9.67 | 67.59% | Buy |
| IMVT | Immunovant | $29.08 | $42.83 | 47.28% | Buy |
| ASND | Ascendis Pharma | $146.59 | $189.07 | 28.98% | Buy |
| BGNE | BeiGene | $197.51 | $247.75 | 25.44% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.77 | $52.17 | 19.19% | Buy |
| BPMC | Blueprint Medicines | $86.51 | $101.50 | 17.33% | Buy |
| NRIX | Nurix Therapeutics | $24.83 | $27.57 | 11.04% | Buy |
| KYMR | Kymera Therapeutics | $47.30 | $51.10 | 8.03% | Buy |
| KRYS | Krystal Biotech | $189.26 | $191.00 | 0.92% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
IMAB Forecast FAQ
Is I-Mab a good buy?
Yes, according to 2 Wall Street analysts, I-Mab (IMAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of IMAB's total ratings.
What are I-Mab's analysts' financial forecasts?
I-Mab's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $14.17M (high $14.17M, low $14.17M), average EBITDA is $-4.778M (high $-4.778M, low $-4.778M), average net income is $-482M (high $-482M, low $-482M), average SG&A $128.76M (high $128.76M, low $128.76M), and average EPS is $-5.951 (high $-5.951, low $-5.951). IMAB's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $963.66M (high $963.66M, low $963.66M), average EBITDA is $-325M (high $-325M, low $-325M), average net income is $980.16M (high $980.16M, low $980.16M), average SG&A $8.76B (high $8.76B, low $8.76B), and average EPS is $12.66 (high $12.66, low $12.66).